Search
Relay Therapeutics Inc
RLAYAdd to Watchlist
18.370USD
-0.400-2.13%
Close 08-28 16:00（ET）
3.48BMarket Cap
LossP/E TTM
Forecast
Currency: USD Updated: 2026-08-28The current earnings forecast score of Relay Therapeutics Inc is 8.71, ranking 72 out of 377 in the Biotechnology & Medical Research industry. The average price target is 14.50, with a high of 19.00 and a low of 6.00.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
27.000
Target Price
+43.85%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
497
Total
6
Median
7
Average
Company name
Ratings
Analysts
Relay Therapeutics Inc
RLAY
14
argenx SE
ARGX
28
Beigene Ltd
ONC
28
Ionis Pharmaceuticals Inc
IONS
25
IQVIA Holdings Inc
IQV
25
Kymera Therapeutics Inc
KYMR
23
1
2
3
...
100
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Relay Therapeutics Inc's expected revenue for the next quarter?
Relay Therapeutics Inc's expected revenue is 727.27K.
What is Relay Therapeutics Inc's price target?
Analysts forecast that Relay Therapeutics Inc's price target is USD 14.50, with the highest forecast at USD 19.00 and the lowest forecast at USD 6.00.
How have Relay Therapeutics IncRLAY's recent earnings per share performed?
The market expectation was USD -0.41, while Relay Therapeutics IncRLAY's earnings per share (EPS) for the previous quarter was USD -0.41. EPS for the next quarter is expected at USD -0.40.
What is the analyst rating for Relay Therapeutics Inc?
Based on the ratings of Relay Therapeutics Inc's stock from 14 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.